Biogen Reports Quarterly Revenues of $3.1 Billion

Go back to Biogen Reports Quarterly Revenues of $3.1 Billion

Biogen (BIIB) PT Raised to $355 at Leerink Partners

October 25, 2017 7:29 AM EDT

Leerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.

... More

SPINRAZA Confusion Creates a Buying Opportunity in Biogen (BIIB) - Stifel

October 24, 2017 11:58 AM EDT

Stifel analyst Thomas Shrader reiterated a Buy rating and $430 price target on Biogen (NASDAQ: BIIB) saying SPINRAZA confusion is an opportunity.

"Some SPINRAZA confusion based in flattish U.S. sales in the face of 75% patient number increase," Shrader commented. "We expect the 2Q revenue... More

Biogen (BIIB) Tops Q3 EPS by 61c

October 24, 2017 7:00 AM EDT

Biogen (NASDAQ: BIIB) reported Q3 EPS of $6.31, $0.61 better than the analyst estimate of $5.70. Revenue for the quarter came in at $3.1 billion versus the consensus estimate of $3.03 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

... More